Novo Nordisk (NYSE: NVO) updates DKK 7,533,256,457 share repurchases

Rhea-AI Filing Summary

Novo Nordisk A/S is continuing its B-share buybacks under a programme initiated 6 May 2026 within EU Safe Harbour Rules, as part of an overall share repurchase programme of up to DKK 15 billion during a 12-month period beginning 4 February 2026. Under the 6 May 2026 programme, the company may repurchase B shares for up to DKK 11,200,000,010.45 between 6 May 2026 and 1 February 2027.

Between 27 July and 3 August 2026, Novo Nordisk executed multiple daily B-share purchases, bringing total repurchases under the 6 May 2026 programme to 12,305,000 B shares for DKK 3,733,256,468. After these transactions, it holds 44,249,480 B shares of DKK 0.10 as treasury shares, equal to 1.0% of its 4,465,000,000 A and B shares. Since 4 February 2026, the company has repurchased 27,064,179 B shares at an average price of DKK 278.35 per share, for a total of DKK 7,533,256,457.

Key Figures

Overall repurchase capacity: DKK 15 billion Sub-programme capacity: DKK 11,200,000,010.45 Shares repurchased under 6 May programme: 12,305,000 B shares +5 more

8 metrics

Overall repurchase capacity DKK 15 billion Maximum size of the share repurchase during a 12-month period beginning 4 February 2026

Sub-programme capacity DKK 11,200,000,010.45 Maximum B-share repurchases under the programme from 6 May 2026 to 1 February 2027

Shares repurchased under 6 May programme 12,305,000 B shares Accumulated purchases under the 6 May 2026 share repurchase programme as of 3 August 2026

Value repurchased under 6 May programme DKK 3,733,256,468 Transaction value of accumulated purchases under the 6 May 2026 programme

Treasury B shares held 44,249,480 B shares Held as treasury shares, corresponding to 1.0% of the share capital after reported transactions

Total A and B shares 4,465,000,000 shares Total amount of A and B shares in the company including treasury shares

Shares repurchased since 4 February 2026 27,064,179 B shares Total B shares repurchased in the overall programme as of 3 August 2026

Total repurchase value since 4 February 2026 DKK 7,533,256,457 Transaction value of 27,064,179 B shares repurchased at an average price of DKK 278.35 per B share

Key Terms

share repurchase programme, treasury shares, Safe Harbour Rules, MAR, +1 more

5 terms

share repurchase programme financial

"initiated a share repurchase programme in accordance with Article 5"

A share repurchase programme is a company's plan to buy back its own shares from the market. This reduces the total number of shares available, which can increase the value of remaining shares and signal confidence in the company's health. For investors, it can indicate that the company believes its stock is undervalued and may lead to higher share prices.

treasury shares financial

"owns a total of 44,249,480 B shares of DKK 0.10 as treasury shares"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

Safe Harbour Rules regulatory

"Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules")"

MAR regulatory

"in accordance with Article 5 of Regulation No 596/2014 ... (MAR)"

A market abuse regulation is a set of legal rules that forbid insider trading and deliberate manipulation of security prices and require fair disclosure of important company information. It works like a referee for markets, giving investors confidence that trades reflect real supply and demand rather than secret tips or engineered price moves, which helps protect the value of investments and the integrity of market prices.

ADRs financial

"Its ADRs are listed on the New York Stock Exchange (NVO)."

American Depositary Receipts (ADRs) are certificates issued by a U.S. bank that stand in for shares of a foreign company, allowing those shares to be bought and sold on U.S. stock exchanges in U.S. dollars. Think of an ADR as a local ticket representing a foreign stock: it makes trading, settlement, and tax reporting simpler for U.S. investors, but still exposes them to risks like currency moves, different accounting rules, and foreign corporate practices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/04/2026 - 10:39 AM Accepted by SEC EDGAR 08/04/2026 - 10:39 AM Learn about SEC filing dates

FAQ

What is the size and duration of Novo Nordisk (NVO) current share repurchase programme?

Novo Nordisk plans to repurchase up to DKK 15 billion of B shares during a 12-month period beginning 4 February 2026, with a sub-programme allowing up to DKK 11,200,000,010.45 of B-share buybacks from 6 May 2026 to 1 February 2027.

How many Novo Nordisk (NVO) shares were repurchased between 27 July and 3 August 2026?

From 27 July to 3 August 2026, Novo Nordisk made daily B-share purchases of 195,000, 190,000, 185,000, 185,000, 200,000 and 190,000 shares, bringing accumulated purchases under the 6 May 2026 programme to 12,305,000 B shares.

How many treasury shares does Novo Nordisk (NVO) hold after the latest buybacks?

After the reported transactions, Novo Nordisk holds 44,249,480 B shares of DKK 0.10 as treasury shares, corresponding to 1.0% of its share capital out of a total of 4,465,000,000 A and B shares including treasury shares.

What has Novo Nordisk (NVO) repurchased since 4 February 2026 under its overall programme?

Since 4 February 2026, Novo Nordisk has repurchased a total of 27,064,179 B shares at an average price of DKK 278.35 per share, resulting in a cumulative transaction value of DKK 7,533,256,457 under its ongoing B-share buyback programme.

Under which rules is Novo Nordisk (NVO) conducting its share repurchase programme?

The B-share repurchase initiated 6 May 2026 is carried out under Article 5 of Regulation No 596/2014 and Commission Delegated Regulation (EU) 2016/1052, referred to as the EU Safe Harbour Rules governing compliant share buybacks.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

August 4, 2026

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 4 August 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 27 July 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	11,160,000		3,362,368,903
27 July 2026	195,000	324.55	63,286,944
28 July 2026	190,000	330.16	62,729,800
29 July 2026	185,000	335.98	62,155,883
30 July 2026	185,000	333.15	61,632,345
31 July 2026	200,000	315.08	63,016,376
3 August 2026	190,000	305.61	58,066,217
Accumulated under the programme	12,305,000		3,733,256,468

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

Page 2 of 2

With the transactions stated above, Novo Nordisk owns a total of 44,249,480 B shares of DKK 0.10 as treasury shares, corresponding to 1.0% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12- month period beginning 4 February 2026. As of 3 August 2026, Novo Nordisk has since 4 February 2026 repurchased a total 27,064,179 B shares at an average share price of DKK 278.35 per B share equal to a transaction value of DKK 7,533,256,457.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown	Liz Skrbkova (US)
+45 3079 9289	+1 609 917 0632
globalmedia@novonordisk.com	USMediaRelations@novonordisk.com
Investors:
Michael Novod	Sina Meyer
+45 3075 6050	+45 3079 6656
nvno@novonordisk.com	azey@novonordisk.com
Max Ung	Christoffer Sho Togo Tullin
+45 3077 6414	+45 3079 1471
mxun@novonordisk.com	cftu@novonordisk.com
Alex Bruce	Mads Berner Bruun
+45 3444 2613	+45 3075 2936
axeu@novonordisk.com	mbbz@novonordisk.com
Ida Schaap Melvold	Frederik Taylor Pitter (US)
+45 3077 5649	+1 609 613 0568
idmg@novonordisk.com	fptr@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 46 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: August 4, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer